Wir sind mit live! Mehr erfahren

Schrodinger

SDGR

Börsenwert 1,69 Mrd. $

22,60 USD

-2,88

11,3 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

22,40

-0,20

0,88 %

1 Tag

-11,3 %

5 Tage

-16,61 %

1 Monat

-5,56 %

3 Monate

44,87 %

6 Monate

87,4 %

Seit Jahresbeginn

25,7 %

1 Jahr

11,28 %

5 Jahre

-57,55 %

10 Jahre

-21,09 %

Profil: Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Mitarbeiter: 850

Gesundheitswesen Gesundheitsinformationsdienste

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 25 %

Neutral 70 %

Negativ 5 %

Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced the publication of new research in Nature that reveals critical insights into the atomic-scale structure of lithium-ion battery (LIB) electrolytes. In a joint study with researchers from Columbia University and the New York Structural Biology Center, the team discovered new insights that challenge long-held assumptions of the fundamental chemistry of lithium-ion batteries, including multi-lithium ion complexes that may.

Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

Zacks Investment Research

Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?

Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?

Selling the Meta rally, Schrödinger's Apple, Tesla from faith to hope | Market Hang

Meta jumped 11% on Monday on early traction for its Muse AI agent, and Interactive Brokers chief strategist Steve Sosnick says his own customers were selling into it: Meta was the most sold stock on the platform. Ross Gerber makes the bear case on social media and the bull case on Nvidia.

Selling the Meta rally, Schrödinger's Apple, Tesla from faith to hope | Market Hang

Schrödinger: Company Creation Is Now The Real Drug Business

Schrödinger, Inc. has undergone significant changes, including pipeline cuts and a strategic pivot away from solo clinical development. Despite software growth deceleration and pipeline setbacks, SDGR's financials improved with the Ajax sale and a stronger balance sheet. SDGR's net income turned positive in Q2 2026, aided by a $48.9M gain from Ajax and increased cash reserves to $418.8M.

Schrödinger: Company Creation Is Now The Real Drug Business

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company's common stock to three newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducem.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zacks Investment Research

Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?

Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger announced the formation of Tectora, a biotech it co-founded with NEA and RA Capital, focused on immunology and inflammation therapies.

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery wi.

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Zacks Investment Research

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt